Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
Stocktwits on MSN
Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results
An investigational intravesical drug-releasing system with erdafitinib is designed to provide prolonged release of erdafitinib directly into the bladder via intravesical administration. ・The company ...
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System Performance. International ...
The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), either with or without ...
Oncology Media Relations Oncology_media_relations@its.jnj.com Investor contact: Jess Margevich investor-relations@its.jnj.com ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results